Biomea Fusion, Inc. (BMEA)
BMEA moved a median of -0.36% 30 minutes after news, and -0.56% by the close. How BMEA actually reacts to news — the realized, point-in-time move the market made, measured across 427 labeled events over the last three years with zero look-ahead.
BMEA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.13% | 44% | 422 |
| 30-min | -0.36% | 42% | 424 |
| 60-min | -0.32% | 47% | 424 |
| to close | -0.56% | 39% | 424 |
| Middle 50% of BMEA reactions | -2.04% to +1.15% |
|---|---|
| Median reaction (30-min) | -0.36% |
| Measured reactions | 427 |
Half of all Biomea Fusion, Inc. news events land between -2.04% and +1.15% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BMEA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | -2.08% | 23% | -2.94% |
| Analyst downgrades | 12 | -1.04% | 42% | +2.86% |
| Coverage initiations | 18 | -0.79% | 39% | -3.63% |
| Rating reiterations | 100 | -0.36% | 37% | -1.23% |
| Price-target cuts | 13 | -0.25% | 31% | +2.19% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how BMEA ranks against every other measured name →
That’s how BMEA usually reacts — get an email when it moves on news →Email me when BMEA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BMEA's baseline. Nothing else.
Recent BMEA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Biomea Fusion, Inc. For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -8.77% | -16.49% | |
| Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist | Press release | GlobeNewswire | -8.77% | -16.49% | |
| Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist | Press release | GlobeNewswire | -0.70% | -11.27% | |
| Biomea Fusion Announces Termination of Proposed Public Offering of Securities | Press release | GlobeNewswire | -5.29% | -15.29% | |
| Biomea Fusion Announces Proposed Public Offering of Securities | Press release | GlobeNewswire | -5.29% | -15.29% | |
| Form 8-K Biomea Fusion, Inc. For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -5.29% | -15.29% | |
| Biomea Fusion to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.78% | -1.04% | |
| Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes | Press release | GlobeNewswire | +4.01% | +4.61% | |
| Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity | Press release | GlobeNewswire | +2.76% | +0.79% | |
| Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights | Press release | GlobeNewswire | +0.80% | +0.00% | |
| Form 10-Q Biomea Fusion, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.80% | +0.00% | |
| Form 8-K Biomea Fusion, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | +0.00% | |
| Form 8-K Biomea Fusion, Inc. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +1.29% | +2.59% | |
| Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study | Press release | GlobeNewswire | -7.72% | -6.50% | |
| Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity | Press release | GlobeNewswire | -1.16% | -5.80% | |
| Biomea Fusion to Participate at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | -6.33% | |
| Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights | Press release | GlobeNewswire | -1.90% | +0.00% | |
| Form 10-Q Biomea Fusion, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.90% | +0.00% | |
| Form 8-K Biomea Fusion, Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -1.90% | +0.00% | |
| Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions | Press release | GlobeNewswire | -0.12% | -2.44% | |
| Form 8-K Biomea Fusion, Inc. For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +0.58% | -11.05% | |
| Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment | Press release | GlobeNewswire | +0.58% | -11.05% | |
| Form ARS Biomea Fusion, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.58% | -11.05% | |
| Form DEF 14A Biomea Fusion, Inc. For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | +0.58% | -11.05% | |
| Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies | Press release | GlobeNewswire | +2.93% | +15.04% | |
| Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights | Press release | GlobeNewswire | +3.51% | +7.02% | |
| Form 10-K Biomea Fusion, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.51% | +7.02% | |
| Form 8-K Biomea Fusion, Inc. For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +3.51% | +7.02% | |
| Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 | Press release | GlobeNewswire | +0.36% | -10.71% | |
| Form 8-K Biomea Fusion, Inc. For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | +2.17% | |
| Biomea Fusion to Participate at Upcoming Investor Conferences | Press release | GlobeNewswire | -1.54% | +1.54% | |
| Form 8-K Biomea Fusion, Inc. For: Jan 14 | SEC filing · Form 8-K | SEC EDGAR | -5.42% | -15.96% | |
| Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones | Press release | GlobeNewswire | +3.17% | +0.00% | |
| Form S-8 Biomea Fusion, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.39% | +4.72% | |
| Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.06% | -2.17% | |
| Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 | Press release | GlobeNewswire | -0.36% | +11.59% | |
| Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) | Press release | GlobeNewswire | -1.55% | -10.95% | |
| Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) | Press release | GlobeNewswire | -1.84% | -6.15% | |
| Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.84% | -6.15% | |
| Biomea Fusion to Participate at Upcoming Investor Conferences | Press release | GlobeNewswire | +2.91% | +4.12% | |
| Biomea Fusion to Participate at Jefferies London Healthcare Conference | Press release | GlobeNewswire | -1.07% | -2.14% | |
| Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025 | Press release | GlobeNewswire | +3.89% | +8.94% | |
| Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights | Press release | GlobeNewswire | +3.89% | +8.94% | |
| Form 10-Q Biomea Fusion, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.89% | +8.94% | |
| Form 8-K Biomea Fusion, Inc. For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +3.89% | +8.94% | |
| Biomea Fusion to Present Poster Presentations at ObesityWeek®2025 | Press release | GlobeNewswire | -0.37% | -2.21% | |
| Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist | Press release | GlobeNewswire | +1.35% | -4.05% | |
| Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series | Press release | GlobeNewswire | -0.32% | -8.86% | |
| Biomea Fusion Announces Pricing of Public Offering of Securities | Press release | GlobeNewswire | -7.00% | -7.75% | |
| Form 8-K Biomea Fusion, Inc. For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -3.97% | -11.11% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BMEA section they belong to.
Where else BMEA is measured.
BMEA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Biomea Fusion, Inc.'s median reaction calculated?
Every labeled BMEA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 427 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of BMEA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BMEA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.